Targeted Therapies in Adult B-Cell Malignancies

Table 2

Clinical trials for lymphoma: (a) for follicular lymphoma; (b) for Mantle cell lymphoma, based on https://clinicaltrials.gov/, as of March 13, 2015. PD-L-1: programmed death-1 ligand 1; CTLA-4: cytotoxic T-lymphocyte-associated protein 4; HDAC: histone deacetylase; PI3k: phosphoinositide 3-kinase; BTK: Bruton’s tyrosine kinase; Cdk: cyclin-dependent kinase; bcl2: B-cell lymphoma 2; PARP: poly(ADP-ribose) polymerase; ASCT: autologous stem cell transplantation.

(a)

Follicular lymphoma; 1031 studies	Monoclonal antibodies; 232 studies	Anti-PD-1	2 studies	Combination with rituximab
		CD20 radio	34 studies	Combination
		immunotherapy	including	+ ASCT
			Phase 3
		CD45 ^131I	1 study	+ ASCT
			Phase 2
		Anti-CTLA-4	1 study	Combination with SD-
				101 (TLR9 agonist)
		Anti-CD20	10 studies	+ lenalidomide
			Phase 1	maintenance
			Phase 2
		Bevacizumab	Phase 1	Combination
			Phase 1	+ vandetanib
		Apolizumab	Phase 1
		(anti-DR)	Phase 2
		Galiximab (anti-CD80)	Phase 2; 1 study	+ rituximab
		Anti-CD19	Phase 1
			2 studies
		Anti-CD22	Phase 1/2	+ ASCT
		Radioimmunotherapy	Phase 2/3
		Cold	Phase 1
		Anti-CD74	Phase 1/2	Combination with rituximab
		Anti-CD20+IL12
		Anti-v3 integrin	Phase 1
		Anti-CD80	Phase 1/2
		BMK120	Phase 1	Rituximab
		Buparlisib
	PI3K inhibitor	BAY80-6946	Phase 2
		Idelalisib	Phase 3	Combination
		Entospletinib		Phase 1
	BTK inhibitor	Ibrutinib/ONO 4059; Spebrutinib	Phase 2	10 studies
	Anti-CDK	Flavopiridol	Phase 1	Combination
		Antisense	Phase 2	Combination with rituximab
	Anti-Bcl-2		2 studies
		Obatoclax	Phase 1/2
	Anti-PARP	Alisertib; Veliparib	Phase 2; Phase 1/2	Combination
	HDAC	Vorinostat	Phase 2	+ rituximab
	Anti-kinase	Vandetanib	Phase 1

(b)

		Anti-CD20
		Rituximab	Phase 2	Chemo, vorinostat,
			Phase 3	bortezomib
		Ofatumumab	Phase 1
		Ublituximab  ^90Y/^131I		+ lenalidomide
				maintenance
				+ ASCT
		51 studies
		Anti-CD56  ^131I
		3 studies	Phase 1	+ ASCT
		Anti-VEGF
	Monoclonal antibodies; 158 studies	bevacizumab	Phase 2	3 studies
		Anti-VEGF kinase
		(cediranib)	Phase 1	+ bevacizumab
		Anti-transferrin R	Phase 1
		Anti-CTLA4	Phase 1/2	4 studies
		Anti-HLA DR	2 studies	Phase 1
		Anti-CD22	Phase 1	1 study
		Anti-CD22 ^90Y	Phase 1/2	+ anti-CEA In111 1 study
Mantle cell lymphoma; 860 studies		Anti-CD22 In111	Phase 1/2
		Anti--v 3 integrin	Phase 1
		Anti-CD19	Phase 1/2
		Anti-CD74	Phase 1/2	+ veltuzumab (humanized MoAb)
		Anti-IGF-1R	Phase 1/2
		ganitumab
		Anti-TRAIL R2	Phase 1	+ bortezomib/vorinostat
		conatumumab
	Anti-PI3K	Idelalisib	Phase 1	Chemo/rituximab
		BKM120	Phase 1	+ rituximab
	Anti-BTK	Ibrutinib	Phase 1	Chemo/rituximab
	Anti-cdk	Flavopiridol	Phase 1	+ chemo/rituximab
	mTOR inhibitor	Temsirolimus	Phase 2	+ rituximab
			Phase 1/2	+ cladribine/rituximab
	Anti-endosialin/TEM1		Phase 1
	HDAC	Romidepsin	Phase 1/2	+ rituximab/lenalidomide
	Anti-bcl2	Oblimersen	Phase 2	+ rituximab
		Obatoclax		+ chemo/rituximab
	Aurora-kinase inhibitor	Alisertib	Phase 2	+/− rituximab
	Dehydrogenase inhibitor	CPI-613	Phase 1	+ bendamustine/rituximab
	HDAC	Vorinostat	Phase 1/2	+ chemo
	Toll-R agonists	CPG 7909	Phase 2	+ chemo